Sentiment-Signal
25,7
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Unternehmen & Branche
| Name | Harmony Biosciences Holdings, Inc. |
|---|---|
| Ticker | HRMY |
| CIK | 0001802665 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,81 Mrd. USD |
| Beta | 0,89 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 868,453,000 | 158,687,000 | 2.71 | 1,271,631,000 | 870,218,000 |
| 2025-09-30 | 10-Q | 239,455,000 | 50,865,000 | 0.87 | 1,208,218,000 | 835,123,000 |
| 2025-06-30 | 10-Q | 200,489,000 | 39,776,000 | 0.68 | 1,108,008,000 | 773,080,000 |
| 2025-03-31 | 10-Q | 184,733,000 | 45,560,000 | 0.78 | 1,055,535,000 | 720,525,000 |
| 2024-12-31 | 10-K | 714,734,000 | 145,493,000 | 2.51 | 999,200,000 | 659,155,000 |
| 2024-09-30 | 10-Q | 186,038,000 | 46,093,000 | 0.79 | 928,135,000 | 596,804,000 |
| 2024-06-30 | 10-Q | 172,814,000 | 11,591,000 | 0.20 | 858,383,000 | 538,583,000 |
| 2024-03-31 | 10-Q | 154,615,000 | 38,334,000 | 0.67 | 846,985,000 | 515,394,000 |
| 2023-12-31 | 10-K | 582,022,000 | 128,853,000 | 2.13 | 811,448,000 | 466,992,000 |
| 2023-09-30 | 10-Q | 160,268,000 | 38,461,000 | 0.63 | 777,766,000 | 481,332,000 |
| 2023-06-30 | 10-Q | 134,216,000 | 34,300,000 | 0.56 | 760,183,000 | 485,172,000 |
| 2023-03-31 | 10-Q | 119,126,000 | 29,485,000 | 0.48 | 715,092,000 | 443,041,000 |
| 2022-12-31 | 10-K | 437,855,000 | 181,468,000 | 2.97 | 673,870,000 | 402,838,000 |
| 2022-09-30 | 10-Q | 117,206,000 | 87,943,000 | 1.44 | 643,464,000 | 343,884,000 |
| 2022-06-30 | 10-Q | 107,028,000 | 23,531,000 | 0.39 | 505,034,000 | 246,533,000 |
| 2022-03-31 | 10-Q | 85,313,000 | 21,485,000 | 0.35 | 464,005,000 | 214,503,000 |
| 2021-12-31 | 10-K | 305,440,000 | 34,597,000 | 0.58 | 433,443,000 | 186,507,000 |
| 2021-09-30 | 10-Q | 80,732,000 | -9,620,000 | -0.17 | 391,092,000 | 152,018,000 |
| 2021-06-30 | 10-Q | 73,821,000 | 14,117,000 | 0.24 | 359,695,000 | 126,551,000 |
| 2021-03-31 | 10-Q | 59,674,000 | 7,386,000 | 0.13 | 337,252,000 | 107,879,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-26 | Kapadia Sandip | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -3,746 | 37.15 | -139,171.39 | -26,8% | |
| 2026-01-15 | Kapadia Sandip | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -20,961 | 35.92 | -752,833.18 | -145,2% | |
| 2025-12-12 | Dayno Jeffrey M. | Director, Officer, PRESIDENT, CEO | Open Market Sale | -5,933 | 40.11 | -237,956.61 | -45,9% | |
| 2025-12-12 | Dayno Jeffrey M. | Director, Officer, PRESIDENT, CEO | Open Market Sale | -20,000 | 40.11 | -802,146.00 | -154,7% | |
| 2025-12-05 | Kapadia Sandip | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -20,000 | 39.54 | -790,896.00 | -152,5% | |
| 2025-11-21 | Kapadia Sandip | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -3,427 | 35.00 | -119,945.00 | -23,1% | |
| 2025-08-15 | Kapadia Sandip | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -21,573 | 36.50 | -787,377.83 | -151,8% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.